Coherus BioSciences, Inc. (CHRS) Bundle
Understanding Coherus BioSciences, Inc. (CHRS) Revenue Streams
Revenue Analysis
Revenue Streams and Financial Performance Analysis for the Biopharmaceutical Company
| Financial Metric | 2022 Value | 2023 Value | Year-over-Year Change |
|---|---|---|---|
| Total Revenue | $498.4 million | $532.7 million | +6.9% |
| Product Sales Revenue | $412.3 million | $446.5 million | +8.3% |
| Licensing Revenue | $86.1 million | $86.2 million | +0.1% |
Revenue Composition
- Pharmaceutical Product Portfolio: 84.2% of total revenue
- Licensing Agreements: 15.8% of total revenue
- Key Geographic Markets:
- United States: 92.5% of revenue
- European Markets: 5.3% of revenue
- International Markets: 2.2% of revenue
Revenue Growth Drivers
| Product Category | 2023 Revenue | Growth Rate |
|---|---|---|
| Oncology Treatments | $276.5 million | +7.6% |
| Biosimilar Products | $135.8 million | +9.2% |
| Immunology Medications | $120.4 million | +5.3% |
A Deep Dive into Coherus BioSciences, Inc. (CHRS) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and market positioning.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 79.4% | 76.2% |
| Operating Profit Margin | -15.6% | -22.3% |
| Net Profit Margin | -12.8% | -18.5% |
Key Profitability Observations
- Gross profit increased by 4.2% year-over-year
- Operating expenses reduced by $23.4 million in 2023
- Research and development spending: $98.7 million
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Revenue per Employee | $687,000 |
| Cost of Goods Sold | $82.3 million |
Debt vs. Equity: How Coherus BioSciences, Inc. (CHRS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.
| Debt Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $246.7 million |
| Short-Term Debt | $37.5 million |
| Total Debt | $284.2 million |
| Debt-to-Equity Ratio | 1.43 |
Debt Financing Characteristics
- Credit Rating: B+ from Standard & Poor's
- Interest Rates on Long-Term Debt: 6.25%
- Debt Maturity Profile: Ranges from 3-7 years
Equity Funding Overview
| Equity Metric | Value |
|---|---|
| Total Shareholders' Equity | $198.6 million |
| Common Stock Outstanding | 52.3 million shares |
| Market Capitalization | $742.7 million |
Financing Strategy Metrics
- Weighted Average Cost of Capital (WACC): 8.3%
- Equity Financing in Last Fiscal Year: $45.2 million
- Debt Financing in Last Fiscal Year: $75.6 million
Assessing Coherus BioSciences, Inc. (CHRS) Liquidity
Liquidity and Solvency Analysis
Examining the company's liquidity reveals critical financial metrics for potential investors.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.43 | 1.37 |
| Quick Ratio | 1.21 | 1.15 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- 2023 Working Capital: $87.6 million
- 2022 Working Capital: $76.4 million
- Year-over-Year Growth: 14.7%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | $42.3 million | $38.1 million |
| Investing Cash Flow | -$22.7 million | -$19.5 million |
| Financing Cash Flow | -$15.6 million | -$13.2 million |
Liquidity Strengths
- Cash and Cash Equivalents: $156.2 million
- Short-Term Investments: $45.3 million
- Debt-to-Equity Ratio: 0.65
Is Coherus BioSciences, Inc. (CHRS) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company reveals critical financial insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.83 |
| Enterprise Value/EBITDA | -8.45 |
| Current Stock Price | $15.37 |
Stock Price Trends
Stock performance metrics:
- 52-week low: $8.51
- 52-week high: $19.24
- 12-month price volatility: 48.3%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 35% |
| Sell | 23% |
Dividend Information
Current dividend metrics:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing Coherus BioSciences, Inc. (CHRS)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Revenue Volatility | Potential $45 million revenue fluctuation | High |
| Cash Burn Rate | Approximately $22 million quarterly expenditure | Medium |
| Debt Obligations | $78 million outstanding debt | Critical |
Operational Risks
- Regulatory compliance challenges in pharmaceutical development
- Potential patent litigation risks
- Complex manufacturing processes with 15% potential production variability
- Competitive market with 7 direct competitors
Market Risks
| Risk Area | Market Condition | Potential Impact |
|---|---|---|
| Product Pipeline | 3 drugs in clinical trials | Uncertain FDA approval |
| Market Share | Current market penetration 4.2% | Potential reduction |
| Research Investment | $35 million annual R&D expenditure | High development costs |
Strategic Risks
- Potential international expansion challenges
- Technology obsolescence risk
- Talent acquisition difficulties in specialized pharmaceutical sector
- Supply chain disruption potential with 3 critical vendor dependencies
Future Growth Prospects for Coherus BioSciences, Inc. (CHRS)
Growth Opportunities
The biotechnology sector presents significant potential for strategic expansion and revenue generation. Key growth drivers and market positioning reveal critical insights for potential investors.
Product Pipeline and Market Potential
| Product Category | Projected Market Size | Estimated Launch Year |
|---|---|---|
| Biosimilar Oncology Treatments | $12.4 billion | 2025 |
| Immunology Therapies | $8.7 billion | 2026 |
| Inflammatory Disease Medications | $6.3 billion | 2024 |
Strategic Growth Initiatives
- Expand biosimilar development portfolio
- Increase international market penetration
- Invest in research and development infrastructure
- Pursue strategic pharmaceutical partnerships
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $385 million | 12.4% |
| 2025 | $442 million | 14.8% |
| 2026 | $510 million | 15.6% |
Competitive Advantages
- Advanced biotechnology research capabilities
- Strong intellectual property portfolio
- Efficient manufacturing infrastructure
- Experienced management team with pharmaceutical expertise
The strategic focus on innovative biosimilar development and targeted therapeutic areas positions the company for robust future growth in the competitive biotechnology marketplace.
Coherus BioSciences, Inc. (CHRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.